Aclaris Therapeutics (ACRS) Reports Q4 Loss, Tops Revenue Estimates

Financial Performance - Aclaris Therapeutics reported a quarterly loss of $0.30 per share, better than the Zacks Consensus Estimate of a loss of $0.37, and improved from a loss of $0.41 per share a year ago [1] - The company achieved an earnings surprise of 18.92% and has surpassed consensus EPS estimates in all four of the last quarters [1] - Revenues for the quarter ended December 2023 were $17.57 million, exceeding the Zacks Consensus Estimate by 344.14%, compared to $7.75 million in the same quarter last year [1] Market Performance - Aclaris shares have increased by approximately 15.2% since the beginning of the year, outperforming the S&P 500's gain of 6.3% [2] - The stock currently holds a Zacks Rank 3 (Hold), indicating it is expected to perform in line with the market in the near future [3] Future Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.33 on revenues of $1.17 million, and for the current fiscal year, it is -$1.05 on revenues of $13.36 million [4] - The Medical - Drugs industry is ranked in the top 41% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% [4] Competitor Insights - OmniAb, Inc. is expected to report a quarterly loss of $0.17 per share, reflecting a year-over-year change of -342.9%, with revenues anticipated to be $6.94 million, down 80.4% from the previous year [5]